## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.32 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($12.35)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Acadia Healthcare Company, Inc. (ACHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: CBS 42 | 20251211T161004 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Acadia Healthcare Company, Inc. The firm encourages stockholders who purchased Acadia Healthcare securities prior to February 28, 2020, and continue to hold them, to contact them to assist with the investigation. The investigation specifically concerns whether the Company and its officers/directors engaged in corporate misconduct.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: Louisiana First News | 20251210T161105 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (ACHC) following the company's disclosure of higher anticipated expenses related to patient-related litigation. Acadia revised its full-year 2025 Adjusted EBITDA guidance downwards and projected a significant increase in PLGL expense due to higher settlement costs, increased claim frequency, and less favorable reinsurance terms. Investors who purchased Acadia securities are encouraged to learn more about the investigation.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: MyStateline | 20251210T231004 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (ACHC) following the company's disclosure of significantly higher anticipated patient-related litigation costs and a reduced outlook for full-year 2025 Adjusted EBITDA. The firm is encouraging investors who purchased Acadia securities to join their investigation into potential claims. This decline in financial projections led to a drop in Acadia's stock price.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Stockholders to Learn More About the Investigation**
- Source: MyChamplainValley.com | 20251209T160911 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Acadia Healthcare Company, Inc. The firm encourages investors who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to come forward and assist in the investigation. Investors can find more information and contact the firm through their website or by phone.

**5. Bronstein, Gewirtz & Grossman, LLC Encourages Acadia Healthcare Company, Inc. (ACHC) Stockholders to Inquire about Securities Investigation**
- Source: SiouxlandProud | 20251211T161004 | Neutral | Relevance: 97%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. (ACHC) securities. This investigation follows Acadia's disclosure on December 2, 2025, that it expects higher expenses related to patient-related litigation, leading to a reduction in its full-year 2025 Adjusted EBITDA guidance and a significant increase in projected PLGL expenses. As a result, Acadia's stock price dropped, prompting the firm to encourage affected stockholders to inquire about the securities investigation.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 10)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |
| 2025-12-03 | Keybanc | $25 | $30 | -17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |
| 2025-12-03 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (18.7%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 37.3% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (10 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 18.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.3 |
| Current P/E | 6.9 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -6.8% to -8.0% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.8%) - potential reversal signal. AM_20 at -6.0% indicates price below own 20MA trend. Underperforming sector by 5.7pp, stock-specific weakness. Below SMA200 (0.63x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -8.03% (CS: 3) | Weak |
| RSI_14 | 35.4 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 0.940x | Below |
| vs SMA50 | 0.723x | Below |
| vs SMA200 | 0.627x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $14.45
- **Stop Loss:** $12.35 (14.5% risk)
- **Target:** $18.65 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 657
- **Position Value:** $9,493.65
- **Portfolio %:** 9.49%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*